ST Huluwa (605199.SH) and related responsible persons received a warning letter from the Hainan Securities Regulatory Bureau

Zhitongcaijing · 1d ago

Zhitong Finance App News, ST Huluwa (605199.SH) issued an announcement. On July 17, 2026, the company received the “Decision on Issuing Warning Letter Measures against Hainan Huluwa Pharmaceutical Group Co., Ltd. and Liu Jingping” (2026) No. 26 issued by the Hainan Regulatory Bureau of the China Securities Regulatory Commission.

After investigation, Hainan Zhongwang Medical Technology Development Co., Ltd. (Zhongwang Medical for short) is an enterprise controlled by the same actual controller as the company, and is a related party to the company. From 2023 to 2025, transactions involving the company and Zhongwang Medical did not comply with related transaction review procedures and information disclosure in accordance with regulations, and were not reviewed and disclosed until April 2026.

The above acts of the company violate the provisions of Article 3 (1) and Article 41 of the “Administrative Measures on Information Disclosure of Listed Companies” (CSRC Order No. 182) and Article 3 (1) and 42 of the “Administrative Measures on Information Disclosure of Listed Companies” (CSRC Order No. 226). Liu Jingping, then chairman and general manager of the company, failed to perform his duties faithfully and diligently, and was mainly responsible for the company's irregularities. The Hainan Securities Regulatory Bureau decided to take administrative supervision measures to issue a warning letter against the company and Liu Jingping, and record it in the capital market integrity file database.